Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521327 | 1.00 | KMT2A (0.47) | KMT2AMEN1ALKBH5FTOALDH1A1 | |
| SCHEMBL23003601 | 0.85 | MEN1 (0.53) | KMT2AMEN1ALDH1A1KDM4ETSHR | |
| SCHEMBL1040521 | 0.80 | PKM (0.59) | KMT2AALKBH5FTOALDH1A1 | |
| SCHEMBL4667670 | 0.79 | ALDH1A1 (0.51) | KMT2AMEN1ALKBH5FTOALDH1A1 | |
| SCHEMBL11922718 | 0.76 | DPP7 (0.51) | KMT2AALKBH5FTOALDH1A1KDM4E | |
| SCHEMBL1253621 | 0.75 | ALDH1A1 (0.51) | KMT2AMEN1ALKBH5FTOALDH1A1 | |
| SCHEMBL11693746 | 0.75 | HRH2 (0.55) | KMT2AMEN1 | |
| SCHEMBL27510406 | 0.75 | DPP7 (0.55) | KMT2AMEN1ALKBH5FTOALDH1A1 | |
| SCHEMBL109279 | 0.75 | ALDH1A1 (0.67) | KMT2AMEN1ALDH1A1KDM4ETSHR | |
| SCHEMBL650684 | 0.74 | ALDH1A1 (0.55) | KMT2AMEN1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706727-B1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | ACELOT INC (US) | 2024-07-31 | — | — | EP | claimed |
| EP-3706727-B1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | ACELOT INC (US) | 2024-07-31 | — | — | EP | disclosed |
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | ACELOT, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230331658-A1 | Small Molecule Drugs and Related Methods for Treatment of Diseases Related to Abeta42 Oligomer Formation | ACELOT, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| EP-3706727-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | Acelot, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | KMT2A 4242/4885MEN1 1428/4885ALKBH5 4814/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | KMT2A 3426/4885MEN1 1060/4885ALKBH5 4741/4885 |
| US-20230331658-A1 | Small Molecule Drugs and Related Methods for Treatment of Diseases Related to Abeta42 Oligomer Formation | APP, PSEN2, PSEN1 | KMT2A 4242/4885MEN1 1428/4885ALKBH5 4814/4885 |
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | APP, PSEN2, BACE1 | KMT2A 2137/4885MEN1 1305/4885ALKBH5 4122/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | KMT2A 4242/4885MEN1 1428/4885ALKBH5 4814/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | KMT2A 4255/4885MEN1 4558/4885ALKBH5 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.